Man Group plc Makes New $1.66 Million Investment in Keros Therapeutics, Inc. $KROS

Man Group plc bought a new position in Keros Therapeutics, Inc. (NASDAQ:KROS) during the second quarter, Holdings Channel.com reports. The firm bought 155,541 shares of the company’s stock, valued at approximately $1,664,000.

Other institutional investors also recently modified their holdings of the company. Caitong International Asset Management Co. Ltd grew its holdings in shares of Keros Therapeutics by 254.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock valued at $33,000 after acquiring an additional 1,166 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in Keros Therapeutics by 149.2% during the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock worth $42,000 after acquiring an additional 1,888 shares during the period. Legal & General Group Plc purchased a new position in Keros Therapeutics in the second quarter worth $90,000. XTX Topco Ltd purchased a new position in Keros Therapeutics in the fourth quarter worth $212,000. Finally, New York State Common Retirement Fund grew its stake in Keros Therapeutics by 264.1% in the 2nd quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock valued at $142,000 after purchasing an additional 7,700 shares during the period. 71.56% of the stock is owned by institutional investors.

Analyst Ratings Changes

KROS has been the subject of several research analyst reports. Zacks Research raised Keros Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 27th. Wall Street Zen raised shares of Keros Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, August 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Keros Therapeutics in a report on Wednesday, August 12th. Leerink Partners decreased their price objective on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a report on Tuesday, August 4th. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Keros Therapeutics in a research note on Tuesday, August 4th. Four investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Keros Therapeutics has an average rating of “Hold” and an average price target of $20.50.

Insider Buying and Selling at Keros Therapeutics

In other news, insider Lorena Raquel Lerner sold 3,568 shares of Keros Therapeutics stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total value of $36,714.72. Following the completion of the transaction, the insider owned 27,559 shares in the company, valued at $283,582.11. This trade represents a 11.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Alpna Seth sold 2,625 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $10.72, for a total transaction of $28,140.00. Following the completion of the sale, the director directly owned 9,767 shares in the company, valued at approximately $104,702.24. This trade represents a 21.18% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,768 shares of company stock valued at $144,979 in the last three months. 12.60% of the stock is owned by company insiders.

Keros Therapeutics Price Performance

Shares of KROS opened at $11.07 on Wednesday. Keros Therapeutics, Inc. has a 1 year low of $9.69 and a 1 year high of $22.55. The stock’s fifty day moving average price is $10.78 and its two-hundred day moving average price is $11.48. The firm has a market cap of $219.52 million, a PE ratio of -2.99 and a beta of 1.01.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. Sell-side analysts anticipate that Keros Therapeutics, Inc. will post -5.27 earnings per share for the current fiscal year.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.